SGLT-2 Inhibitors for Individuals With Diabetes and Chronic Kidney Disease

Michael D. North, MD

Alexei O. DeCastro, MD

American Family Physician. 2024;110(6):570A-570B.

Author disclosure: No relevant financial relationships.

MICHAEL D. NORTH, MD, and ALEXEI O. DeCASTRO, MD, Medical University of South Carolina, Charleston

Address correspondence to Michael D. North, MD, at northm@musc.edu.

Author disclosure: No relevant financial relationships.

1.Natale P, Tunnicliffe DJ, Toyama T, et al. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024(5):CD015588.
2.Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5s):s1-s127.
3.World Health Organization. Diabetes. Accessed September 2, 2024. https://www.who.int/health-topics/diabetes
4.Raghavan S, Vassy JL, Ho YL, et al. Diabetes mellitus–related all cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8(4):e011295.
5.Centers for Disease Control and Prevention. National Diabetes Statistics report, 2014. Accessed November 11, 2024. https://stacks.cdc.gov/view/cdc/23442/cdc_23442_DS1.pdf

This series is coordinated by Christopher W. Bunt, MD, AFP assistant medical editor, and the NNT Group.

A collection of Medicine by the Numbers published in AFP is available at https:// www.aafp.org/afp/mbtn.

My account